Why the study?
Altered signal complexity had mostly been studied comparing patients with few or no comorbidities against healthy controls, leaving its utility in heterogeneous clinical settings unknown.
Brain signal complexity measured by multiscale entropy can differentiate various neurological and non-neurological disorders, offering complementary information to spectral power.
MSE may index broader health status including non-neurological comorbidities in clinical EEG; leaves open its specificity as a neurological biomarker.
Brain signal variability changes across the lifespan in both health and disease, likely reflecting changes in information processing capacity related to development, aging and neurological disorders. While signal complexity, and multiscale entropy (MSE) in particular, has been proposed as a biomarker for neurological disorders, most observations of altered signal complexity have come from studies comparing patients with few to no comorbidities against healthy controls. In this study, we examined whether MSE of brain signals was distinguishable across patient groups in a large and heterogeneous set of clinical-EEG data. Using a multivariate analysis, we found unique timescale-dependent differences in MSE across various neurological disorders. We also found MSE to differentiate individuals with non-brain comorbidities, suggesting that MSE is sensitive to brain signal changes brought about by metabolic and other non-brain disorders. Such changes were not detectable in the spectral power density of brain signals. Our findings suggest that brain signal complexity may offer complementary information to spectral power about an individual's health status and is a promising avenue for clinical biomarker development.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: